1h Free Analyst Time
The radiopharmaceuticals market is forecasted to grow byUSD 6.28 billion during 2023-2028, accelerating at a CAGR of 12.17% during the forecast period. The report on the radiopharmaceuticals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising incidence of neurological disorders, growing cancer cases rising investment in the oncology market, and minimal side effects of radiopharmaceuticals.
The radiopharmaceuticals market is segmented as below:
By Source
- Cyclotrons
- Nuclear reactors
By End-user
- Diagnostics
- Therapeutics
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the radiopharmaceuticals market covers the following areas:
- Radiopharmaceuticals market sizing
- Radiopharmaceuticals market forecast
- Radiopharmaceuticals market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Source
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global radiopharmaceuticals market: Bayer AG, Bracco Spa, Cardinal Health Inc., Curium Pharma, Eckert and Ziegler AG, General Electric Co., IBA Radiopharma Solutions, Jubilant Pharmova Ltd., Lantheus Holdings Inc., Mallinckrodt Plc, NorthStar Medical Radioisotopes LLC, Novartis AG, NTP Radioisotopes SOC Ltd., PharmaLogic Holdings Corp., Positron Corp., Radiomedix Inc., Siemens AG, Sinotau Pharmaceuticals, Sotera Health Co., and Telix Pharmaceuticals Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is the production of cyclotron-based radiopharmaceuticals."
According to the report, one of the major drivers for this market is the rising incidence of neurological disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Bracco Spa
- Cardinal Health Inc.
- Curium Pharma
- Eckert and Ziegler AG
- General Electric Co.
- IBA Radiopharma Solutions
- Jubilant Pharmova Ltd.
- Lantheus Holdings Inc.
- Mallinckrodt Plc
- NorthStar Medical Radioisotopes LLC
- Novartis AG
- NTP Radioisotopes SOC Ltd.
- PharmaLogic Holdings Corp.
- Positron Corp.
- Radiomedix Inc.
- Siemens AG
- Sinotau Pharmaceuticals
- Sotera Health Co.
- Telix Pharmaceuticals Ltd.
